Eight Stock Selections to Capitalize on a Robust Sector of the Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Should l Buy ADMA?
Source: MarketWatch
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Shares Drop 15% Amid Short Report
- Impact of Short Report: ADMA Biologics' shares fell 15% following a short report from Culper Research, indicating market concerns about the company's future performance, which could undermine investor confidence and shareholder value.
- Lack of Response: ADMA did not immediately respond to Seeking Alpha's request for comment, raising questions about the company's transparency and communication capabilities, potentially exacerbating investor unease.
- Share Repurchase Plan: ADMA announced a $125 million accelerated share repurchase agreement with JPMorgan, aiming to enhance earnings per share by reducing the float, which, despite the current stock decline, reflects the company's confidence in its intrinsic value.
- Future Revenue Forecast: ADMA forecasts $635 million in revenue for 2026, driven by ASCENIV and new supply agreements, indicating long-term growth potential despite facing short-term pressures.
See More
Adma Biologics Shares Drop After Short Report
- Stock Price Decline: Shares of Adma Biologics Inc. (ADMA) fell 6% on Tuesday following Culper Research's announcement of a short position, indicating strong investor concern regarding the company's future performance.
- Short Selling Allegations: Culper Research accused Adma's reported growth of being a “fiction,” claiming it is largely driven by a de facto channel stuffing scheme and undisclosed related party distributors, which could have long-term reputational implications for the company.
- Revenue Forecast Downgrade: Culper estimates that without channel stuffing, Adma's revenues will decline by 3% in 2025, contrasting sharply with the reported 20% growth, which may erode investor confidence in the company's future profitability.
- Market Reaction: Investors can receive updates on this developing story directly on Stocktwits, reflecting heightened market scrutiny and anxiety regarding Adma's future developments.
See More
Five Stocks Added to Zacks Rank #1 (Strong Buy) List
- Earnings Growth: Lifetime Brands (LCUT) has seen a 35.6% increase in its current year earnings estimate over the past 60 days, indicating strong growth potential in the kitchenware design and marketing sector, which could drive stock price appreciation.
- Oilfield Services Demand: Enerflex Ltd. (EFXT) has experienced a 19.5% rise in its current year earnings estimate in the last 60 days, reflecting robust demand in the natural gas and petroleum production services market, likely enhancing its competitive position.
- Automotive Supply Chain Strength: Magna International (MGA) has seen a 13.9% increase in its current year earnings estimate over the past 60 days, suggesting that its expertise in vehicle engineering and contract manufacturing will further enhance its market share.
- Biopharmaceutical Market Potential: ADMA Biologics (ADMA) has reported a 12.9% increase in its current year earnings estimate, indicating growing market demand in the treatment of immunodeficient patients, which could lead to significant revenue growth for the company.
See More
ADMA Biologics Announces $200 Million Capital Return Initiative
- Capital Return Initiative: ADMA Biologics has announced a capital return initiative targeting approximately $200 million in 2026, including a $125 million accelerated share repurchase agreement with JPMorgan, highlighting the company's commitment to enhancing shareholder value.
- Repurchase Agreement Details: Under the ASR agreement, ADMA will pay JPMorgan an upfront amount of $125 million and is expected to initially receive about 6.4 million shares of common stock around March 3, 2026, representing approximately 80% of the anticipated repurchased shares, reflecting confidence in the current stock price.
- Progress on Buyback Program: Since the authorization of the buyback program in May 2025, ADMA has repurchased approximately $160 million of its common stock, indicating a disciplined and opportunistic approach to capital allocation aimed at enhancing long-term shareholder value.
- Future Outlook: ADMA forecasts revenue of $635 million for 2026, as ASCENIV drives margin expansion and new supply agreements extend the growth runway, positioning the company for continued success.
See More
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript
See More
ADMA Biologics Reports Strong 2025 Financial Results
- Significant Revenue Growth: ADMA Biologics reported total revenue of $510 million for 2025, reflecting a 20% year-over-year increase, demonstrating the company's disciplined execution across its commercial and financial platforms, which enhances market confidence and investor expectations.
- Substantial EBITDA Increase: The adjusted EBITDA for 2025 reached $231 million, a 40% year-over-year growth, indicating ongoing improvements in operational leverage and cost management, further solidifying the company's profitability.
- Strong Ascentive Product Performance: Ascentive achieved net revenue of $363 million in 2025, marking a 51% year-over-year increase, driven by robust demand and widespread physician adoption of its patented immune globulin, indicating significant growth potential ahead.
- Leadership Transition and Strategic Adjustments: CFO Brad Tade announced his retirement, with Terry Kohler stepping in, bringing extensive public company experience that is expected to further optimize capital efficiency and cash flow, supporting the company's long-term growth strategy.
See More
ADMA Biologics Shares Drop 15% Amid Short Report
- Impact of Short Report: ADMA Biologics' shares fell 15% following a short report from Culper Research, indicating market concerns about the company's future performance, which could undermine investor confidence and shareholder value.
- Lack of Response: ADMA did not immediately respond to Seeking Alpha's request for comment, raising questions about the company's transparency and communication capabilities, potentially exacerbating investor unease.
- Share Repurchase Plan: ADMA announced a $125 million accelerated share repurchase agreement with JPMorgan, aiming to enhance earnings per share by reducing the float, which, despite the current stock decline, reflects the company's confidence in its intrinsic value.
- Future Revenue Forecast: ADMA forecasts $635 million in revenue for 2026, driven by ASCENIV and new supply agreements, indicating long-term growth potential despite facing short-term pressures.
See More
Adma Biologics Shares Drop After Short Report
- Stock Price Decline: Shares of Adma Biologics Inc. (ADMA) fell 6% on Tuesday following Culper Research's announcement of a short position, indicating strong investor concern regarding the company's future performance.
- Short Selling Allegations: Culper Research accused Adma's reported growth of being a “fiction,” claiming it is largely driven by a de facto channel stuffing scheme and undisclosed related party distributors, which could have long-term reputational implications for the company.
- Revenue Forecast Downgrade: Culper estimates that without channel stuffing, Adma's revenues will decline by 3% in 2025, contrasting sharply with the reported 20% growth, which may erode investor confidence in the company's future profitability.
- Market Reaction: Investors can receive updates on this developing story directly on Stocktwits, reflecting heightened market scrutiny and anxiety regarding Adma's future developments.
See More
Five Stocks Added to Zacks Rank #1 (Strong Buy) List
- Earnings Growth: Lifetime Brands (LCUT) has seen a 35.6% increase in its current year earnings estimate over the past 60 days, indicating strong growth potential in the kitchenware design and marketing sector, which could drive stock price appreciation.
- Oilfield Services Demand: Enerflex Ltd. (EFXT) has experienced a 19.5% rise in its current year earnings estimate in the last 60 days, reflecting robust demand in the natural gas and petroleum production services market, likely enhancing its competitive position.
- Automotive Supply Chain Strength: Magna International (MGA) has seen a 13.9% increase in its current year earnings estimate over the past 60 days, suggesting that its expertise in vehicle engineering and contract manufacturing will further enhance its market share.
- Biopharmaceutical Market Potential: ADMA Biologics (ADMA) has reported a 12.9% increase in its current year earnings estimate, indicating growing market demand in the treatment of immunodeficient patients, which could lead to significant revenue growth for the company.
See More
ADMA Biologics Announces $200 Million Capital Return Initiative
- Capital Return Initiative: ADMA Biologics has announced a capital return initiative targeting approximately $200 million in 2026, including a $125 million accelerated share repurchase agreement with JPMorgan, highlighting the company's commitment to enhancing shareholder value.
- Repurchase Agreement Details: Under the ASR agreement, ADMA will pay JPMorgan an upfront amount of $125 million and is expected to initially receive about 6.4 million shares of common stock around March 3, 2026, representing approximately 80% of the anticipated repurchased shares, reflecting confidence in the current stock price.
- Progress on Buyback Program: Since the authorization of the buyback program in May 2025, ADMA has repurchased approximately $160 million of its common stock, indicating a disciplined and opportunistic approach to capital allocation aimed at enhancing long-term shareholder value.
- Future Outlook: ADMA forecasts revenue of $635 million for 2026, as ASCENIV drives margin expansion and new supply agreements extend the growth runway, positioning the company for continued success.
See More
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript
See More
ADMA Biologics Reports Strong 2025 Financial Results
- Significant Revenue Growth: ADMA Biologics reported total revenue of $510 million for 2025, reflecting a 20% year-over-year increase, demonstrating the company's disciplined execution across its commercial and financial platforms, which enhances market confidence and investor expectations.
- Substantial EBITDA Increase: The adjusted EBITDA for 2025 reached $231 million, a 40% year-over-year growth, indicating ongoing improvements in operational leverage and cost management, further solidifying the company's profitability.
- Strong Ascentive Product Performance: Ascentive achieved net revenue of $363 million in 2025, marking a 51% year-over-year increase, driven by robust demand and widespread physician adoption of its patented immune globulin, indicating significant growth potential ahead.
- Leadership Transition and Strategic Adjustments: CFO Brad Tade announced his retirement, with Terry Kohler stepping in, bringing extensive public company experience that is expected to further optimize capital efficiency and cash flow, supporting the company's long-term growth strategy.
See More
